Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.

Citation: Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY.: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Bioorg Med Chem, Volume 22 (7), 2014
Authors: Choi HH, Chong W, Hyun KH, Kim H, Kim KB, Lee BM, Lee DH, Nam SY., Park K
Journal: Bioorg Med Chem
Year: 2014
DOI: 10.1016/j.bmc.2014.02.009
PubMed: 24588963
Machine-readable: REST API RDF

Publication